ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO682

A Strategy for Reducing Cysts in Autosomal Dominant Polycystic Kidney Disease with a CFTR Corrector

Session Information

Category: Genetic Diseases of the Kidney

  • 1001 Genetic Diseases of the Kidney: Cystic

Authors

  • Cebotaru, Liudmila, Johns Hopkins University, Baltimore, Maryland, United States
  • Yanda, Murali K., Johns Hopkins School of Medicine, Baltimore, Maryland, United States
Background

ADPKD is associated with progressive enlargement of cysts. Mutations in pkd1 and pkd2 induce growth-related pathways, including heat shock proteins raising the prospect that pharmacological interventions that target these pathways might alleviate or prevent ADPKD. The purpose of our study was to demonstrate a role for VX-809, a corrector of cystic fibrosis transmembrane conductance regulator (CFTR), in reducing cyst growth.

Methods

We used the Pkd1fl/fl; Pax8rtTA; TetO-cre mouse model which, when treated with doxycycline, allows for the ablation of PC1. These mice, where injected IP with doxycycline (4 µg of doxycycline/g body weight) on postnatal days (PND)11, PND12, and PND13, to induce multiple large cysts and large polycystic kidneys at approximately 3 weeks of age. Kidneys were harvested, sectioned and analyzed.

Results

Mice injected daily with VX-809 (30 mg/kg) from PND10 to PND20 showed significantly less cyst growth (see Fig 1). VX-809 improved renal function, as evidenced by a lower blood urea nitrogen (BUN) and creatinine. In proximal tubule-derived, Pkd1-knockout cells and in cystic kidneys, VX-809 reduced both basal and forskolin-activated cAMP levels, inhibited cyst growth and reduced levels of the heat shock proteins Hsp27, 70, and 90 which are upregulated in cystic kidneys. In the cystic mice, VX-809 decreased an ER stress marker, the GADD153 protein, cell proliferation, and apoptosis. Importantly in proximal tubule-derived, cultured Pkd1-knockout cells, VX-809 increased the activity of the sodium proton exchanger, NHE3 which is down regulated in these cells.

Conclusion

VX-809 reduces the ability of cysts to grow by reducing the levels of HSPs and restore the NHE3 activity in proximal tubule cells. VX-809 could potentially be a new way to treat patients with ADPKD.

Fig. 1: Cystic mice kidneys before and after treatment with VX-809. See text for details.